The MoFo BioMeter for the first quarter of 2014 shows a decrease in average BioMeter value in a quarter dominated by early stage deals. Total dealmaking activity showed an uptick compared to the same quarter in 2013.
In the first quarter of 2014, the average BioMeter value for all transactions was approximately $15.9 million, a decrease compared to the same quarter in 2013. As with the same quarter in 2013, the BioMeter value for the first quarter in 2014 was influenced significantly by a deal by Moderna Therapeutics, this one with Alexion, which had a $100 million up-front payment and covered 10 compounds. Also impacting the results for Q1 was the AnaptysBio/Tesaro transaction for up to three products. If the upfront payments for each of these transactions had been divided by the number of products, the average BioMeter value would have been approximately $10.3 million.
Please see full report below for more information.
Firefox recommends the PDF Plugin for Mac OS X for viewing PDF documents in your browser.
We can also show you Legal Updates using the Google Viewer; however, you will need to be logged into Google Docs to view them.
Please choose one of the above to proceed!
LOADING PDF: If there are any problems, click here to download the file.